Single chain CD40L fusion polypeptides

• US 9,340,599 B2
• Filed: 12/02/2014
• Issued: 05/17/2016
• Est. Priority Date: 07/21/2008
• Status: Active Grant

• Current Assignee: Apogenix AG
• Original Assignee: Apogenix AG
• Inventors: Hill, Oliver, Gieffers, Christian, Thiemann, Meinolf
• Primary Examiner(s): LANDSMAN, ROBERT S
• Application Number:
  US14/558,681
• Publication Number:
  US 20150110734A1
• Time in Patent Office: 532 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/525 Tumour necrosis factor [TNF]
• CPC Class Codes: C07K 14/70575 NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 NGF C07K14/48, TNF C07K14/525
• CPC Class Codes: C07K 14/70578 NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 NGF-receptor C07K14/71, TNF-receptor C07K14/7151
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 2317/41 Glycosylation, sialylation, or fucosylation
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/22 containing a Strep-tag
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C07K 2319/32 : fusions with soluble part of a cell surface receptor, "decoy receptors"
• CPC Class Codes: C07K 2319/35 : containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
• CPC Class Codes: C07K 2319/74 : containing a fusion for binding to a cell surface receptor
• CPC Class Codes: C12N 15/62 : DNA sequences coding for fusion proteins
• CPC Class Codes: C12N 15/79 : Vectors or expression systems specially adapted for eukaryotic hosts

Abstract

The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

Claims

1. A single-chain fusion polypeptide comprising:

(i) a first soluble CD40 ligand (CD40L) cytokine domain,

(ii) a first peptide linker,

(iii) a second soluble CD40L cytokine domain,

(iv) a second peptide linker, and

(v) a third soluble CD40L cytokine domain,

wherein each of the soluble CD40L cytokine domains lacks a stalk region and the first and the second peptide linkers independently have a length of 3-8 amino acids.

2. The polypeptide of claim 1, wherein the first, the second, and the third soluble CD40L cytokine domains are independently an N-terminally shortened domain of SEQ ID NO:

5, and optionally comprises an amino acid mutation.

3. The polypeptide of claim 1, wherein the first, the second, and the third soluble CD40L cytokine domains independently have the amino sequence of 112-261, 117-261, or 121-261 of SEQ ID NO:

5.

4. The polypeptide of claim 1, wherein the first, the second, and the third soluble CD40L cytokine domains have the amino sequence of 121-261 of SEQ ID NO:

5.

5. The polypeptide of claim 1, wherein the first and second peptide linkers are independently glycine/serine linkers.

6. The polypeptide of claim 5, wherein the glycine/serine linkers comprise substituted asparagine residues.

7. The polypeptide of claim 1, wherein the first and second peptide linkers are independently selected from the group consisting of SEQ ID NOs:

52-53 and SEQ ID NO;

21-26.

8. The polypeptide of claim 1, which additionally comprises an N-terminal signal peptide domain.

9. The polypeptide of claim 8, wherein the N-terminal signal peptide domain comprises a protease cleavage site.

10. The polypeptide of claim 1, which additionally comprises a further domain at the N-terminal and/or C-terminal end.

11. The polypeptide of claim 10, wherein the further domain is a Fab or Fc fragment domain.

12. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 1.

13. An isolated host cell or a non-human organism transformed or transfected with the nucleic acid molecule of claim 12.

14. A pharmaceutical composition comprising the fusion polypeptide of claim 1 and a pharmaceutically acceptable carrier, diluent and/or adjuvant.

15. The polypeptide of claim 1, which additionally comprises a further domain of Fc fragment and a third peptide linker at the C-terminal end.

16. A dimer comprises two polypeptides of claim 15, wherein the two polypeptides are dimerized via disulfide bridges of the third peptide linkers.